Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 4 studies | 39% ± 21% | |
precursor B cell | 3 studies | 31% ± 7% | |
dendritic cell | 3 studies | 41% ± 15% | |
germinal center B cell | 3 studies | 24% ± 3% |
Insufficient scRNA-seq data for expression of GCSAM at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 302.68 | 328 / 328 | 88% | 3.55 | 157 / 178 |
lung | 95% | 276.69 | 549 / 578 | 88% | 3.68 | 1021 / 1155 |
thymus | 100% | 421.40 | 651 / 653 | 81% | 6.01 | 493 / 605 |
stomach | 75% | 270.50 | 268 / 359 | 76% | 2.36 | 216 / 286 |
bladder | 57% | 130.95 | 12 / 21 | 81% | 3.36 | 406 / 504 |
esophagus | 42% | 72.73 | 606 / 1445 | 96% | 4.54 | 175 / 183 |
breast | 42% | 61.39 | 195 / 459 | 81% | 3.04 | 901 / 1118 |
intestine | 51% | 185.92 | 488 / 966 | 72% | 2.31 | 379 / 527 |
kidney | 66% | 103.47 | 59 / 89 | 47% | 0.87 | 425 / 901 |
skin | 72% | 1506.76 | 1304 / 1809 | 40% | 1.39 | 190 / 472 |
prostate | 70% | 104.31 | 171 / 245 | 39% | 0.75 | 198 / 502 |
lymph node | 0% | 0 | 0 / 0 | 100% | 67.65 | 29 / 29 |
spleen | 100% | 525.14 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.84 | 1 / 1 |
tonsil | 0% | 0 | 0 / 0 | 98% | 7.95 | 44 / 45 |
peripheral blood | 81% | 2658.68 | 754 / 929 | 0% | 0 | 0 / 0 |
uterus | 8% | 7.19 | 13 / 170 | 73% | 2.93 | 336 / 459 |
blood vessel | 41% | 52.51 | 544 / 1335 | 0% | 0 | 0 / 0 |
heart | 22% | 31.09 | 188 / 861 | 0% | 0 | 0 / 0 |
adipose | 18% | 20.99 | 221 / 1204 | 0% | 0 | 0 / 0 |
liver | 1% | 1.11 | 3 / 226 | 14% | 0.40 | 56 / 406 |
ovary | 1% | 0.48 | 1 / 180 | 14% | 0.28 | 59 / 430 |
adrenal gland | 3% | 3.18 | 8 / 258 | 3% | 0.09 | 6 / 230 |
eye | 0% | 0 | 0 / 0 | 4% | 0.07 | 3 / 80 |
brain | 0% | 0.10 | 3 / 2642 | 2% | 0.10 | 15 / 705 |
muscle | 2% | 2.77 | 15 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050855 | Biological process | regulation of B cell receptor signaling pathway |
GO_2000402 | Biological process | negative regulation of lymphocyte migration |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0045159 | Molecular function | myosin II binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0005515 | Molecular function | protein binding |
GO_0003779 | Molecular function | actin binding |
Gene name | GCSAM |
Protein name | Germinal center associated signaling and motility (Germinal center-associated-signaling and motility protein) Germinal center-associated signaling and motility protein (Germinal center B-cell-expressed transcript 2 protein) (Germinal center-associated lymphoma protein) (hGAL) |
Synonyms | GAL GCET2 |
Description | FUNCTION: Involved in the negative regulation of lymphocyte motility. It mediates the migration-inhibitory effects of IL6. Serves as a positive regulator of the RhoA signaling pathway. Enhancement of RhoA activation results in inhibition of lymphocyte and lymphoma cell motility by activation of its downstream effector ROCK. Is a regulator of B-cell receptor signaling, that acts through SYK kinase activation. . |
Accessions | C9IY73 ENST00000495418.5 Q8N6F7 ENST00000460387.6 [Q8N6F7-3] ENST00000487901.1 ENST00000646361.1 ENST00000643065.1 [Q8N6F7-2] C9JY41 ENST00000645314.1 F2Z3F7 ENST00000470085.5 ENST00000308910.9 [Q8N6F7-1] ENST00000488580.5 ENST00000484193.5 [Q8N6F7-2] ENST00000644247.1 [Q8N6F7-3] ENST00000646639.2 [Q8N6F7-1] ENST00000643636.1 ENST00000647520.1 |